Prognosismodifying therapy in patients with CAD: how to optimize treatment?

Authors: Khanyukov A.A., Professor, Doctor of Medical Sciences, Head of the Department of Internal Medicine, State Institution «Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine»


According to the materials of the ХІХ National Congress of Cardiologists of Ukraine, September 26-28, Kyiv

In Ukraine, 10.4 million people suffer from arterial hypertension (AH) and 7.7 million from coronary heart disease (CHD). According to statistics, Ukraine ranks first in Europe in terms of the rate of population decline. The lion’s share of deaths is associated with cardiovascular diseases (CVD): every year in our country, 50 thousand heart attacks and 110 thousand strokes are recorded. How to prevent disaster? For an answer to this and other questions, we turned to the head of the Department of Internal Medicine of the 3rd State Institution “Dnepropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Doctor of Medical Sciences, Professor Aleksey Alexandrovich Khanyukov.

Summing up, I want to note that a multidisciplinary approach to individual nosologies has expanded our understanding of the pathogenesis and approaches to the treatment of individual diseases. Today, in daily practice, cardiologists have to work with PPIs, UDCA drugs, and metabolic therapy. Ulsepan, Choludexan, Ripronat can be effective tools for a doctor in achieving the main goal of therapy – reducing the patient’s cardiovascular risk.

Prepared by Maria Marchuk

ARTICLES FROM CATEGORY
Support of educational events. Participation of World Medicine in the First Congress of Optometrists of Ukraine.
Cetirizine is an effective and safe antihistamine (literature review, results of clinical researches)
All-Ukrainian Scientific and Practical Conference “Aspects of Internal Medicine in Wartime 2024"

PROVE YOU ARE A MEDICAL PROFESSIONAL

Attention: This section is intended for healthcare professionals only. If you are not a medical professional, you can return to the main page by clicking the “No” option

CARD-NOTIFICATION OF AN ADVERSE DRUG REACTION AND/OR LACK OF EFFICACY OF THE MEDICINE

INFORMATION ABOUT THE PATIENT

SUSPECTED AR/LE

Suspected AR (describe each clinical manifestation of the AR with dates and times of onset and end and outcome)/Indication of the LE

INFORMATION ABOUT SUSPECTED MEDICINES

INFORMATION ABOUT RELATED MEDICINES

(with the exception of drugs used to correct the effects of AR/LE)
(concomitant diagnoses, laboratory and instrumental studies, allergy history, pregnancy with gestational age, method of conception, pregnancy outcome (if the pregnancy ended, the date of delivery, type of delivery, etc.)

Information about the messenger

INFORMATION ABOUT THE MEDICAL/PHARMACY SPECIALIST

(if not the notifier)

MESSAGE CARD for the patient

to provide the patient and/or his/her representative with information on adverse drug reactions and/or lack of efficacy of the drug

INFORMATION ABOUT THE PATIENT

Information about the suspected medicine

Information on the prescription of the suspected medicinal product

Information about the messenger

Information about the physician, healthcare facility and place of residence of the patient who had an adverse medicine reaction and/or lack of efficacy of the medicine

розробка сайту Estetic web design